ejpmr, 2025, 12(4), 206-216

SJIF Impact Factor 7.065

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

ANTIFUNGAL: A REVIEW

***[1]Vijay Patel and [2]Deepak Ktiyar**

[1]Research Scholar, Department of Pharmaceutics, Kanpur Institute of Technology and Pharmacy, Kanpur, Uttar Pradesh, India.

[2]Assistant Professor, Kanpur Institute of Technology and Pharmacy, Kanpur, Uttar Pradesh, India.

***Corresponding Author: Vijay Patel**

Research Scholar, Department of Pharmaceutics, Kanpur Institute of Technology and Pharmacy, Kanpur, Uttar Pradesh, India.

Article Received on 09/02/2025 **Article Revised on 29/02/2025** **Article Published on 18/03/2025**

ABSTRACT

Due to host toxicity, resistance, and side effects, the effectiveness of existing antifungal treatments for invasive fungal infections is declining, which presents a serious problem in modern medicine. These infections have drastically increased in recent decades, and their fatality rates have remained high. New resistance patterns, such as concurrent resistance to many antifungal classes, are escalating this problem. Recent developments in our knowledge of the processes behind fungal virulence and resistance have revealed possible new targets for antifungal treatments. To find new antifungal treatments, Techniques such as repurposing of already authorised drugs, high throughput evaluations of natural substances, and chemical genomics-based screens are being researched. The present pipeline is still lacking, with just a few numbers of promising compounds exhibiting unique mechanisms of early stages of clinical development activity, despite the pressing need for effective therapies.

1. INTRODUCTION

Over 1.5 million people die each year from invasive fungal diseases globally, posing a serious and ongoing danger to human health. With estimates indicating 30–40% for invasive candidiasis and 20–30% for both disseminated cryptococcosis and invasive aspergillosis, mortality rates are still startlingly high. Immunocompromised patients receiving severe therapies like chemotherapy, long-term corticosteroid therapy, or organ transplants, as well as those suffering from immunosuppressive diseases like HIV/AIDS, are more susceptible to these infections. Nearly 90% of these fatalities are caused by fungi from the genera Candida, Aspergillus, Cryptococcus, Pneumocystis, Mucor, and Rhizopus. Nonetheless, it is becoming more widely acknowledged that new fungal infections from the Zygomycetes, Fusarium, and Scedosporium families are important contributors to invasive mycoses.

In addition to invasive infections, fungus may also cause superficial infections that affect the skin and mucosal surfaces. Although these infections are less fatal, they nonetheless have a major negative influence on quality of life. While keratinised tissues are impacted by cutaneous and subcutaneous mycoses, are often associated with dermatophyte species including Trichophyton, Epidermophyton, and Microsporum, Malassezia globosa and M. furfur are the main culprits behind superficial mycoses. Most often, the genus Candida is associated with mucosal infections, which are mostly caused by opportunistic yeasts.

Because fungi are eukaryotic and share many cellular features with humans, the development of antifungal drugs is more complicated than that of antibacterial drugs. This increases the possibility of host toxicity. Nowadays, oral, topical, and injectable formulations of the four primary families of antifungal agents—azoles, echinocandins, polyenes, and pyrimidine analogs—are accessible. Furthermore, allylamines, a fifth class, are only used to treat superficial dermatophytic infections. Nevertheless, these antifungal drugs have drawbacks, including toxicity, a narrow range of action, safety issues, and pharmacokinetic restrictions. In an attempt to get around these restrictions and improve treatment effectiveness, the development of innovative medications that focus on the production of fungal cell walls, lipids, and proteins has accelerated due to the growth in antifungal resistance.

2. Classification of antifungal agents



Fig. 1: The Antifungal Agent.

2.1 Inhibitors of ergosterol biosynthesis

Inhibitors of ergosterol biosynthesis target key enzymes involved in the production of ergosterol, impairing the integrity and functionality of fungal cell membranes. The main classes of antifungal agents that inhibit ergosterol biosynthesis include:

- Azoles
- Allylamines
- Morpholines

2.1.1 AZOLES

The most widely used antifungal medications in clinical settings are azoles. Because of their broad-spectrum action, they are often used to treat and prevent fungal infections. Azoles function by blocking the cytochrome P450-dependent enzyme 14α-lanosterol demethylase (CYP51), which is encoded by the ERG11 gene. An important part of the fungal cell membrane, ergosterol, is produced from lanosterol by this enzyme. 14-methylated sterols build up as azoles interfere with the ergosterol production pathway by attaching to the iron in the protoporphyrin unit of the enzyme. Fungal growth and reproduction are hampered by this inhibition.

Variations in medication interactions, antifungal activity, and possible adverse effects are caused by structural changes in the active site of CYP51 between fungus species and mammalian P450 mono-oxygenases. Each azole compound's antifungal properties and safety profile are determined by the particular binding affinity it has with its target enzyme.

Imidazoles and triazoles are the two primary categories of azoles, which are cyclic chemical compounds. Clotrimazole, miconazole, and ketoconazole are the first-generation imidazoles that were originally created for antifungal treatment. However, triazoles generally supplanted them due to their substantial adverse effects, high toxicity, and drug interactions.

Compared to imidazoles, Itraconazole, fluconazole, and the first-generation triazoles, have better safety profiles and a wider range of antifungal activity. Although it has little impact on moulds, Fluconazole is effective against species of Coccidioides, Histoplasma, Blastomyces, Cryptococcus neoformans, and Candida. Targeting both yeasts and Aspergillus species, itraconazole has a wider spectrum of action. Both medications, however, have therapeutic limits since they are not effective against several newly discovered fungal infections, including Mucorales, Fusarium, and Scedosporium. One of the main drawbacks of azoles is that they are fungistatic rather than fungicidal, which leads to an increase in antifungal resistance.

In order to overcome these constraints, a second generation of triazoles was created. The FDA in the United States authorised Voriconazole and Posaconazole in 2002 and 2006, respectively. These triazoles are regarded as fungicidal in contrast to their predecessors and have broad-spectrum action, which includes efficacy against Cryptococcus neoformans, Scedosporium, Zygomycetes, and Fusarium.

Due to its greater effectiveness over many other antifungal drugs, voriconazole was adopted as the first-line therapy for invasive aspergillosis caused by Aspergillus fumigatus. The FDA authorised posaconazole, the azole with the largest antifungal range, for the avoidance of invasive Aspergillus and Candida infections.

Both dermatophytes and nondermatophytes are susceptible to the topical antifungal solution efinaconazole. It works very well to treat Candida spp. infections and onychomycosis. Efinaconazole was licensed by the FDA in 2014 to treat fungal nail infections.

The most recently approved triazole in the US and the EU is isavuconazole, is prescribed for the treatment of invasive aspergillosis and mucormycosis in both oral and intravenous forms. Owing to its increased action against Zygomycetes, such as Rhizopus, Mucor, and Cunninghamella species, it provides benefits over previous azoles. Its intravenous formulation also excludes cyclodextrin, a substance linked to nephrotoxicity in patients.

2.1.2 Allylamines

By acting as reversible, non-competitive inhibitors of squalene epoxidase (ERG1), these synthetic fungicidal agents stop ergosterol from being formed. Squalene is converted into 2,3-squalene epoxide by this enzyme. Squalene builds up when this enzyme is inhibited, increasing the permeability of cell membranes and upsetting cellular structure. Terbinafine and naftifine are important members of this category.

Terbinafine, which was isolated from Streptomyces sp. KH-F12, is effective against filamentous fungus such as Fusarium and Aspergillus. Nail infections are often treated with it. Naftifine has fungistatic action against Candida species and is active against Trichophyton, Epidermophyton, and Microsporum.

2.1.3 Morpholines

Morpholines are a class of synthetic organic compounds containing a six-membered ring structure with both nitrogen and oxygen atoms. These compounds have demonstrated significant biological activity, particularly in the field of antifungal therapy. Morpholines function by inhibiting key enzymes involved in ergosterol biosynthesis, An important part of fungal cell membranes. Morpholines damage the integrity and functioning of the fungal cell membrane by interfering with the formation of ergosterol, which inhibits fungal growth or causes cell death.

One of the most notable morpholine derivatives is amorolfine, This is often used to fungal nail diseases. Amorolfine works by inhibiting two important enzymes, D7–D8 isomerase (ERG2) and D14-reductase (ERG24), both of which are involved in the synthesis of ergosterol. This dual inhibition leads to a buildup of sterol intermediates, further compromising the fungal cell membrane. Due to its effectiveness and relatively low toxicity, amorolfine has become a valuable option in topical antifungal therapy.

2.2 Fungal membrane disruptors

Polyenes are macrocyclic organic compounds that are often referred to as macrolides. These compounds usually have a d-mycosimine group conjugated to a macrolactone ring with 20–40 carbons. Because polyenes are amphiphilic, they may attach to the lipid bilayer of fungal cell membranes and form pore-forming complexes with ergosterol. Fungal cell death results from oxidative damage and cytoplasmic contents leaking out due to these holes' disruption of membrane integrity. According to recent research, Ergosterol may be bound by polyenes such as amphotericin B to form an extramembranous fungicidal sterol "sponge," impairing the membrane's functionality.

The earliest antifungal medications to be utilised in therapeutic settings were polyenes. When compared to other antifungal medicines, they have the widest range of action and are fungicidal. Amphotericin B, natamycin, and nystatin are the three polyenes that are now being used in clinical settings. These substances are naturally occurring substances that were separated from Streptomyces noursei, S. natalensis, and S. nodosum culture broths, respectively.

Both natamycin and nystatin work well against Fusarium, Aspergillus, Candida, and Cryptococcus. While natamycin is used to treat fungal keratosis or corneal infections, nystatin is often used to treat cutaneous, vaginal, and esophageal candidiasis. It is advised to treat infections brought on by Candida, Aspergillus, Fusarium, Mucor, Scedosporium, Cryptococcus, and other filamentous fungus since amphotericin B is effective against a variety of yeasts and fungi.

It is true that polyenes have a weak affinity for cholesterol, which adds to their high toxicity and variety of adverse consequences. Because of their high toxicity and low intestinal absorption, nystatin and natamycin are thus exclusively used topically. The most used polyene for systemic infections is amphotericin B. However, it is given intravenously because of its hydrophobicity and limited gastrointestinal absorption, which might have negative consequences, especially in the liver and kidneys.

Creating novel compounds to lessen the toxicity of these polyenes has been the focus of recent research. Semi-synthetic polyenes have been created to enhance selectivity for ergosterol-containing vesicles, reduce hemotoxicity when compared to amphotericin B, and boost water solubility, and exhibit superior efficacy against strains of Candida albicans that are resistant to

amphotericin B and Saccharomyces cerevisiae. Furthermore, amphotericin B lipid formulations, such as encapsulation in liposomes or ribbon- and disc-like lipid complexes, have decreased host toxicity while increasing the drug's efficacy. Other formulations are also being investigated, such as arabinogalactan complexes and amphotericin B-cochleate preparations.

2.3 Fungal cell wall synthesis

One essential component that gives the fungal cell wall form and stiffness is, and protection to fungal cells. Unlike mammalian cells, which have plasma membranes reinforced by a cytoskeleton, fungal cells rely on their cell walls for structural integrity. The cell wall also serves as a barrier against environmental stress, antifungal agents, and host immune responses. It is primarily composed of polysaccharides such as glucans, chitin, and mannans, and its biosynthesis involves several enzymes and complex pathways.

2.3.1 Inhibitors b-glucan synthesis

Glucans are polysaccharides made up of D-glucose monomers connected by β-(1,3) or β-(1,6)-glucan bonds. β-(1,3) makes up more than half of the fungal cell wall. -D-glucan, the primary structural carbohydrate to which glycoproteins and chitin are attached. Currently, the only antifungal medications that target β-glucan production are the echinocandins, which include micafungin, anidulafungin, and capsafungin. The newest family of antifungals, these medications were licensed by the FDA and EMA more than ten years ago. They work as noncompetitive inhibitors of the β-(1,3)-D-glucan synthase enzyme complex, primarily targeting the Fks1 subunit. Fungal cell death and osmotic instability are caused by this inhibition, which also alters the structure of the developing cell wall.

Fungal natural products are the source of semisynthetic lipopeptides called echinocandins. Anidulafungin is made by chemically altering a fermentation product from Coleophoma empetri, Pneumocandin B produced by Glarea lozoyensis yields capsafungin, whereas echinocandin B from Aspergillus nidulans var. echinulatus yields micafungin, a semisynthetic product. The antifungal activities of echinocandins are attributed to their core structure, which is an R5-positioned cyclic hexapeptide with several side chains. An alkoxytriphenyl group is present in anidulafungin, a complex aromatic substituent is present in micafungin, and a fatty acid is present in capsoffungin.

Because of their large molecular weight, In the digestive system, echinocandins are not well absorbed. Given that mammalian cells lack their target enzyme and they show few pharmacological interactions, they are thought to have great safety profiles with little toxicity. However, their usage is mostly restricted to hospital settings due to their short half-life, which requires IV administration once day. Anidulafungin, micafungin, and capsafungin have fungistatic action against Aspergillus species and fungicidal activity against several Candida strains. Invasive candidiasis and esophageal candidiasis may be treated with micafungin and anidulafungin, while invasive aspergillosis can be treated with capsofungin.

Because of their broad-spectrum antifungal efficacy, efforts to create novel echinocandins are still crucial. Furthermore, echinocandins may be more effective against fungal diseases when combined with azoles or amphotericin B, which may also lower the likelihood of resistance formation.

2.3.2 Chitin synthesis inhibitors

Although it only makes up 3% of the fungal cell wall, chitin is a linear homopolymer of β-(1,4)-linked N-acetylglucosamine units that are covalently bound to β-(1,3)-D-glucan. The structural integrity of the cell wall depends on chitin if its production is interfered with, the cell wall becomes osmotically unstable. Human cells lack chitin, which makes it a prime target for antifungal medications.

The two most researched chitin production inhibitors are polyoxin and nikkomycin. Nikkomycin does not exhibit action against Candida albicans or Candida tropicalis, However, it works well against infections caused by highly chitinous dimorphic fungi. On the other hand, polyoxins are peptidyl nucleoside antifungals that are found naturally and effectively combat phytopathogenic fungus. They function as UDP-N-acetylglucosamine's competitive analogues by attaching themselves to the catalytic region of chitin synthase.

Because of their low in vivo action and hydrolytic instability, polyoxins have limited therapeutic usage despite their promising functionality. Consequently, since 2012, polyoxins have not been further developed. Nonetheless, clinical studies are now being conducted to evaluate Nikkomycin Z's potential for therapeutic usage.

2.4 Sphingolipid's biosynthesis

Apart from their many functions in fungal cells, sphingolipids are vital components of eukaryotic cell membranes and are important in the development of fungal diseases. According to recent research, sphingolipid biosynthesis-related enzymes may be targeted to lessen the aggressiveness of fungal infections.

The cyclic depsipeptide Aureobasidin A is derived from Aureobasidium pullulans and has antifungal activity against a variety of fungi, such as Cryptococcus neoformans, Aspergillus nidulans, Candida albicans, Schizosaccharomyces pombe, Aspergillus niger, Saccharomyces cerevisiae, and Candida glabrata. Its effects are less likely to affect Aspergillus fumigatus. An enzyme called inositol phosphorylceramide (IPC) synthase transfers the phosphoinositol group from phosphatidylinositol (PI) to the 1-hydroxy group of phytoceramide to create IPC, is inhibited by aureobasidin A. Fungal sphingolipid production, which is essential for

cellular signalling and the structural integrity of cell membranes, depends on this process. Since mammalian cells lack IPC synthesis, IPC synthase inhibitors are intriguing options for the creation of antifungal medications.

By altering or swapping amino acids in its sequence, new variants of aureobasidin A have recently been created. The increased activity of these altered compounds against A. fumigatus indicates the possibility of further antifungal uses.

2.5 Nucleic acid synthesis inhibitors

A fluorinated pyrimidine analogue with fungistatic qualities, flucytosine (5-FC; 5-fluorocytosine) inhibits RNA/DNA and protein synthesis and interferes with pyrimidine metabolism. Via the cytosine permease transporter, it penetrates fungal cells, where the enzyme cytosine deaminase transforms it into 5-fluorouracil (5-FU). Protein synthesis is inhibited when UMP pyrophosphorylase further converts 5-FU into 5-fluorouridine monophosphate (5-FUMP), which is then phosphorylated and added to RNA in place of UTP. Additionally, 5-FU is converted to 5-fluorodeoxyuridine monophosphate (5-FdUMP), a potent inhibitor of thymidylate synthase that stops fungal DNA synthesis and nuclear division.

This substance is particularly detrimental to fungi since human cells have little to no cytosine deaminase activity. 5-FC shows effectiveness against certain strains of Cryptococcus and Candida both in vitro and in vivo. However, thymidylate synthase is absent from the majority of filamentous fungus, which mainly limits its efficacy to pathogenic yeasts. 5-FC is usually utilised as an adjuvant treatment rather than as a main therapy since resistance to it is very widespread.

2.6 Protein biosynthesis inhibitors

In 2014, the FDA approved tavaborole, an oxaborole antifungal drug, for the topical treatment of toenail onychomycosis brought on by Trichophyton rubrum and T. mentagrophytes. It has antifungal properties against dermatophytes, moulds, and yeast. Tavaborole functions by blocking leucyl-tRNA synthetase, an enzyme essential to fungal protein synthesis. Together with tRNA, it binds to the enzyme's editing site, blocking the movement of amino acids to the ribosome and stopping the synthesis of proteins. Tavaborole is extremely selective for fungal cells, as shown by has 1,000-fold higher affinity than the human enzyme for fungal leucyl-tRNA synthetase.

Other protein-targeting β-amino acid inhibitors production by blocking isoleucyl-tRNA synthetase include Icofungipen and Cispentacin, which were both isolated from Bacillus cereus culture broth. Both substances have potent antifungal properties against Candida albicans.

The ascomycete Sordaria araneosa's fermentation broth yielded sordarin, which was first identified in 1969. Fungal translation elongation factor 2 (EF2) is inhibited by this substance, whereas the human form of the enzyme is unaffected. At the 30-position, the functional group (R) establishes the strength and range of action of sordarin and its analogues. It has been shown that at least 22 novel strains produce different sordarin analogues. Furthermore, by adding other moieties to the glycoside portion of sordarin, such as trisubstituted tetrahydrofuran rings, alkanesulfonate, alkylthio, morpholinyl, or oxazepane, semi-synthetic derivatives of sordarin have been created. Because of its high specificity, sordarin is a promising option for the creation of novel antifungal drugs.

2.7 Microtubule's biosynthesis inhibitors

A vital structural component of all eukaryotic cells, microtubules are dynamic polymers made up of α- and β-tubulin dimers. Some antifungal medications, such vinblastine and griseofulvin, interfere with microtubule activity.

One of the first natural antifungal agents created was griseofulvin, which was initially extracted from Penicillium griseofulvum in 1939. Its limited range of action, which is confined to dermatophyte fungi that cause illnesses like athlete's foot and ringworm, and hepatotoxicity limit its usage. By attaching itself to tubulin and interfering with the formation of fungal microtubules, glieofulvin inhibits mitosis, which stops fungal cell division and proliferation.

3. Methods for creating novel antifungal substances

Compared to antibacterial medications, there are comparatively few antifungal medicines. Due to their physiological similarities, fungi—eukaryotic organisms that parasitise other eukaryotic hosts—make it more difficult to design safe, all-purpose antifungal medications. Although there are a number of antifungal medications on the market, the majority are fungistatic, with the exception of amphotericin B and a few other substances.

The goal of current research is to find novel targets unique to fungi that are necessary for their growth and that are quite different from human proteins. For example, the pathogenicity of many fungal species seems to depend on the synthesis of trehalose. Cell death and trehalose-6-phosphate buildup result from deletion of TPS2, which encodes trehalose-6-phosphate phosphatase. The creation of targeted inhibitors for Candida albicans Tsp2 has been aided by the recent elucidation of its crystal structure.

They also target Ras GTPases, which are essential for fungal virulence, particularly in hot conditions. As a method for creating antifungal drugs, inhibitors such as farnesyltransferase inhibitors are being investigated to interfere with Ras activity. Furthermore, fungal stress

responses and resistance to antifungal therapies are significantly influenced by calcium/calmodulin signalling. Although tacrolimus and other calcineurin inhibitors are immunosuppressive drugs, research is being done to create non-immunosuppressive versions for antifungal applications.

Another possible target is the Hsp90 heat shock protein, which contributes to fungal resistance to azoles and echinocandins. Improved fungicidal effects have been shown when Hsp90 inhibitors, such geldanamycin, are combined with fluconazole or echinocandins.

It is also encouraging to target the process that produces the cell wall anchor glycosylphosphatidylinositol (GPI). Platforms for screening based on chemical genomics have been used to identify new inhibitors of enzymes such as Gwt1 and Mcd4 in this pathway. Strong action against a variety of Aspergillus and Candida species has been shown by these inhibitors.

Creation of genetic platforms like S. cerevisiae haploinsufficiency profiling (HOP) and CaFT is still crucial for identifying and comprehending new antifungal mechanisms of action.

Chemical genomics-based techniques have been used to identify FDA-approved compounds that enhance fluconazole action against various yeast species. An antifungal combination matrix was developed in order to assess about 86,000 chemical interactions between 3,600 small chemicals and six approved antifungal drugs across four fungus species. A fluconazole-resistant C. albicans isolate's susceptibility testing revealed combinations that might increase the effectiveness of fluconazole. Interestingly, clofazimine, a substance that had no known antifungal action, showed antifungal effects when mixed with a number of antifungal medications already on the market.

In another investigation, gene-drug interactions that potentially result in synergistic medication combinations against C. neoformans were identified using a decision-guiding process and an extensive gene deletion library in C. neoformans. More than 80 percent of the 1,500 gene deletion strains that were investigated had gene-drug interactions. Remarkably, there were relatively few conserved responses found when C. neoformans and S. cerevisiae data were compared, indicating species-specific drug interactions.

Using bioinformatics techniques, 64 potential antifungal targets in Aspergillus fumigatus were found. Among these targets were metabolic enzymes with no near human orthologs that are important in the synthesis of vitamins, lipids, and amino acids. Additional methods for determining fungal-specific targets include in-depth examinations of protein-protein interactions in fungal infections and transcriptome studies in A. fumigatus, which concentrate on changes in gene expression linked to invasion.

Discovery has historically depended on screening large libraries of natural or synthetic small compounds. Notably, natural product screening led to the discovery of two important families of antifungal drugs: polyenes and echinocandins. This method has recently yielded fresh findings. Lesional psoriasis scale preparations included psoriasin, a tiny fungicidal protein that was reported to be effective against filamentous fungus, such as A. fumigatus and Trichophyton rubrum, however they are useless against Candida albicans. Zinc chelators that selectively penetrate fungal cells might be a useful antifungal method, since psoriasin causes fungal death by chelating intracellular zinc.

After 20,000 microbial extracts were screened, Streptomyces humidus produced the cyclic peptide known as humidimycin. Through inhibiting the fungal response pathway for high osmolarity glycerol (HOG), humimycin increases the antifungal activity of caspofungin tenfold while decreasing the protective stress response that caspofungin induces. Humidimycin is a viable antifungal medication option since it has minimal toxicity and Human cells do not have the HOG pathway.

The most often utilised technique for discovering antifungal small compounds is still growth inhibition experiments. It is challenging to correlate growth with optical density (OD) measurements because to the limits of these assays, especially for pathogenic fungi that develop as filaments. Furthermore, they are unable to differentiate between fungistatic and fungicidal drugs and are inefficient in discovering compounds that are active against fungal biofilms. These issues have led to the development of new high-throughput screening assays, many of which use markers like the cytoplasmic enzyme adenylate kinase or dyes that indicate viability, such as AlamarBlue, XTT, and Resazurin, which fluoresce when metabolised by viable cells, to evaluate cellular integrity.

4. Antifungal resistance mechanisms

Natural selection drives the development of antifungal resistance, which allows fungi to adapt and endure in the presence of antifungal medications. Microbes have developed a variety of tactics to thwart the effects of drugs, resulting in widespread resistance to antimicrobial medicines in nature.

The mechanisms of antifungal resistance in a variety of antifungal drugs and fungal infections have been thoroughly investigated at the molecular level. Microorganisms use three primary resistance strategies to evade the fungicidal or fungistatic effects of antifungal drugs: (1) reducing the effective drug concentration, (2) altering the drug target, and (3) altering metabolic pathways to reduce drug toxicity.

One important tactic for reducing intracellular drug concentration is the overexpression of drug efflux pumps. Antifungal drug resistance is often caused by transport systems, such as ATP-binding cassette (ABC) transporters and major facilitator superfamily (MFS) transporters. The primary ABC transporters linked to Candida albicans' azole resistance are CDR1 and CDR2, which aggressively pump medications out of the cell and decrease their intracellular accumulation. The ABC transporters CgCDR1, CgCDR2, and CgSNQ2 are also present in C. glabrata, while AFR1 contributes to Cryptococcus neoformans resistance. Azole resistance in Aspergillus fumigatus and Aspergillus nidulans has also been linked to ABC transporters. FLU1 in C. albicans is uniquely connected to fluconazole resistance, while MDR1 among MFS transporters is linked to azole resistance in C. albicans and C. dubliniensis.

Certain genetic mutations control the upregulation of the ABC and MFS transporters. Drug resistance may be increased by constitutive overexpression of efflux pumps brought on by crucial transcription factors' gain-of-function (GOF) mutations. For instance, C. albicans exhibits higher fluconazole resistance due to GOF mutations in Upc2p. Similarly, Cyp51A overexpression, which results from duplications of 34 and 42 base pairs in its promoter region, mediates azole resistance in A. fumigatus.

The overexpression of genes related to sterol production is another method of lowering the effective medication concentration. By changing ergosterol metabolism, upregulation of ERG11 (encoding 14-α sterol demethylase) and other sterol biosynthesis genes, including ERG1, ERG3, ERG7, ERG9, and ERG25, results in azole resistance.

Additionally, in some medicinally useful fungus, including Aspergillus, Candida, Cryptococcus, Trichosporon, Coccidioides, and Pneumocystis, biofilm development dramatically increases antifungal resistance. Dense, multicellular formations called biofilms are encased in an extracellular matrix made of proteins, polysaccharides, and signalling chemicals. Antifungal agents are sequestered by this matrix's diffusion barrier, which lessens their effectiveness. Biofilm-associated infections are still very difficult, if not impossible, to eliminate, even though echinocandins (such micafungin and capsafungin) and amphotericin B often have in vitro activity against C. albicans biofilms.

Drug target changes are another important mechanism of antifungal resistance. For azoles and echinocandins, this has been well documented. C. albicans point mutations in ERG11 reduce drug binding affinity and cause azole resistance. Many of these variants have a mild effect on posaconazole but particularly reduce fluconazole susceptibility. The most often reported mechanism in A. fumigatus that confers high-level azole resistance in clinical isolates is single mutations in Cyp51A.

The primary reason for echinocandin resistance is point mutations in the FSK1 or FSK2 genes. Aspergillus fumigatus, Scedosporium apiospermum, Candida albicans, Candida glabrata, Candida tropicalis, and Candida krusei have all been discovered to carry these alterations, and they are found in two different hotspot locations called HS1 and HS2. Reduced medication effectiveness and markedly elevated inhibitory concentrations result from these changes in glucan synthase activity.

The most frequent cause of resistance to pyrimidine analogues, including 5-fluorocytosine (5FC), is point mutations in the FUR1 gene. Complete resistance to 5FC and 5-fluorouracil (5FU), its active metabolite, is the outcome of these alterations. Additionally, 5FC resistance in different strains of Candida is caused by mutations in the cytosine deaminase gene.

Alterations in metabolic pathways that result in a loss or significant decrease in their function provide another route of antifungal resistance. For instance, the buildup of harmful methylated sterols is prevented by inactivating the ERG3 gene, which is implicated in the latter stages of ergosterol production. This leads to cross-resistance to all azole medications. Ergosterol in the fungal plasma membrane may also be reduced or eliminated entirely as a result of mutations in ERG2, ERG6, ERG24, and ERG3, among other non-essential genes in this pathway. Furthermore, as was already indicated, FUR1 mutations lessen 5FU's transformation into its toxic metabolites, which in turn lessens Candida glabrata's vulnerability to 5FC. Complete 5FC resistance in C. glabrata may be achieved by a fourfold decrease in FUR1 expression.

Multidrug-resistant (MDR) fungal strains—pathogens that are resistant to at least two classes of antifungal agents—have become more prevalent in recent years, according to studies. It has been shown that resistance to In Candida species, loss-of-function mutations or simultaneous alterations in ERG2, ERG3, ERG5, and ERG11 confer both azoles and amphotericin B.

There have also been documented cases of dual resistance to azoles and echinocandins (such as capsafungin); the resistance mechanisms are most likely a mix of upregulated ABC transporter efflux pumps and FSK2 mutations. Isolates of Candida albicans and Candida lusitaniae have sometimes shown resistance to more than two antifungal classes, however this is uncommon.

According to current trends, Candida glabrata has the largest percentage of resistant isolates, making up over 20% in the US and over 10% of all isolates in the EU. These isolates often exhibit resistance to azoles (such voriconazole and fluconazole) as well as echinocandins. Infections brought on by newly discovered fungal diseases, such as Fusarium species, Zygomycetes, and C.

glabrata that is resistant to azoles and echinocandins, are also become more frequent.

5. Pipeline For Antifungals

The pipeline for antifungal drugs has been severely constrained by their complicated development process and lack of funding, despite the urgent need for novel antifungal medications. However, the U.S. government's recent legislative initiatives have sped up the development of antifungals. The Generating Antibiotic Incentives Now (GAIN) Act extends commercial exclusivity for five years and expedites FDA assessment and fast-track designation for Qualified Infectious Disease Products (QIDPs). Similarly, by offering a seven-year commercial exclusivity term, The development of medications for rare conditions like invasive mycoses is promoted under the Orphan Drug Act.

Improved pharmacokinetics and pharmacodynamics, decreased host toxicity and drug-drug interactions, enhanced range of efficacy against drug-resistant fungi and rare moulds like Scedosporium spp, and innovative, selective mechanisms of action that target fungal cells are all characteristics of the best next-generation antifungal medications. However, since 2006, when anidulafungin was authorised by the FDA and the European Medicines Agency (EMA), no new types of antifungal drugs have been licensed.

Numerous drugs in varying stages of research are part of the current antifungal pipeline. The most promising antifungal medications undergoing preclinical and clinical studies are shown in Table 1. Similar modes of action, such as targeting ergosterol biosynthesis, disrupting fungal membranes, or blocking cell wall production Many of these compounds, which are derivatives of existing azoles, echinocandins, and polyenes, are maintained by β-1,3-D-glucan production.

The most recent triazole to be licensed, isavuconazole, is now being assessed in two phase 3 clinical studies. When treating invasive mould infections brought on by Aspergillus and other filamentous fungus, the SECURE study evaluated its safety and effectiveness in comparison to voriconazole. According to the results, isavuconazole was better tolerated and had fewer side effects than voriconazole when used as a main therapy. Another phase 3 clinical study is now being conducted on isavuconazole to examine its oral and intravenous formulations for the management of candidemia and invasive Candida infections.

A new family of triazoles called VT1129 and VT1161 was created to reduce their affinity for human CYP enzymes, such as CYP51. According to in vitro research, VT1161 is over 1,000 times Around 3,000 times more selective for Cryptococcus isoforms than human CYP51, VT1129 is more selective for Candida CYP51 than the human enzyme.[130] In a mouse model of cryptococcal meningitis, VT1129 is more effective than fluconazole in preventing the growth of C. gattii and Cryptococcus neoformans. VT1129 is now undergoing phase 1 clinical studies to treat cryptococcal meningitis after receiving both The FDA's QIDP designation and orphan drug categorisation. Onychomycosis and recurrent vulvovaginal candidiasis are being treated with VT1161, which is undergoing phase 2b studies and is quite efficient against types of Candida that are resistant to fluconazole.

A new β-1,3-glucan synthase inhibitor, SCY-078 differs from existing echinocandins in its structure. It comes from the fermentation of Hormonema sp. to create enfumafungin, a triterpene glycoside. Strong action is shown by SCY-078 against isolates of Aspergillus and Candida that are resistant to echinocandin, non-Aspergillus moulds, and Scedosporium prolificans, a highly resistant mould with few available treatment options. Furthermore, in peritoneal dialysis patients, It has shown effectiveness against Paecilomyces variotii, a fungus linked to widespread illnesses such peritonitis and fungemia. With its oral formulation now undergoing phase 2 clinical studies for invasive candidiasis and its intravenous (IV) formulation undergoing phase 1 trials, SCY-078 has been designated as a QIDP. To improve oral bioavailability and antifungal efficacy, research is being conducted on semi-synthetic enfumafungin derivatives.

Targeting Aspergillus and Candida species, biafungin is a next-generation echinocandin that works similarly to caspofungin and anidulafungin. Its main benefit, however, is that it has a half-life of around 81 hours, which is four times longer than that of anidulafungin (24 hours), the longest-acting echinocandin to date. Biafungin has a great safety record and little medication interactions, much as other echinocandins. It is now undergoing phase 2 clinical studies to treat candidemia, and the FDA has designated it as an orphan medicine and given it QIDP status. Recently, the competitive chitin synthesis inhibitor nikkomycin Z was designated as an orphan medication. Phase 1 clinical studies are now being conducted to treat coccidioidomycosis.

Promising candidates with distinct modes of action are also emerging in addition to these antifungals. Fungal mitochondrial membranes are disrupted by the new arylamidine T-2307, which hinders the generation of energy necessary for vital cellular processes. The medication is preferentially absorbed by Agp2, a fungal-specific spermine-spermidine transporter with high affinity, indicating that this mechanism is fungus-specific. T-2307 completed phase 1 trials for candidiasis therapy.

Targeting dihydroorotate dehydrogenase (URA1), F901318 is a member of a novel family of antifungals called orotomides, which prevent the manufacture of pyrimidines.[137] Human URA1 is 2,000 times less likely

to be inhibited by this medication than its fungal equivalent, despite the fact that this pathway is preserved in humans. F901318 has little action against Mucorales or Candida species, however it is quite efficient against strains of Aspergillus that are resistant to azoles and amphotericin B. There are now phase 1 clinical trials being conducted to treat invasive aspergillosis.

The fungal Gwt1 protein, which is essential for the first phases of glycosylphosphatidylinositol (GPI) anchor production, is inhibited by APX001A (formerly known as E1210). Mannosylated proteins must be attached to the fungal membrane and cell wall via this anchor. High in vitro efficacy against Scedosporium, Aspergillus, Fusarium, and Candida is shown by APX001A, including strains of Candida that are resistant to azoles and echinocandins. APX001A was recently designated as a QIDP by the FDA and is now undergoing phase 1 clinical studies to treat invasive coccidioidomycosis, invasive aspergillosis, and invasive candidiasis.

A protein kinase inhibitor repurposing search to find antifungal drugs led to the discovery of AR-12 (OSU-03012). It has been approved as a European Orphan Drug to treat cryptococcosis. Through its inhibition of acetyl-CoA synthetase, AR-12 disrupts a number of cellular activities. For the treatment of cryptococcosis, it is now under preclinical research.

Because of its potential for treating aspergillosis, VL-2397, an antifungal drug that belongs to a new class, has been given QIDP classification. Research indicates that the medication penetrates fungal cells via the siderophore transporter Sit1, albeit the precise mechanism of fungal inhibition is yet unknown. This transporter is absent from mammalian cells, suggesting that VL-2397 uptake is exclusive to fungal infections. It is ineffective against Candida albicans and other species of Candida, although it has fungicidal action against Aspergillus. VL-2397 is now undergoing phase 1 clinical trials to treat invasive aspergillosis.

6. CONCLUSIONS

Invasive fungal infections have become much more common in recent years, and the growing use of immunomodulatory treatments has put more people at risk. Even though there are many antifungal medications available, they often fail to adequately treat these infections. Reports of strains resistant to azoles and echinocandins are increasing, mortality rates are still startlingly high, and many of the current therapies have both acute and long-term adverse effects. Expanding the antifungal medication pipeline is urgently needed to address these issues, as many researchers have pointed out.

Although programs like the FDA's GAIN (QIDP designation) and the Orphan Drug Act have aided in the development of antifungal drugs, the pipeline is still small. It is hard to anticipate which compounds, if any, will become effective therapeutic antifungals since there are so few with unique mechanisms of action in preclinical or early clinical studies. The creation of narrow-spectrum medications that target certain diseases may be a more practical strategy given the difficulty of creating broad-spectrum antifungal treatments. Pathogen-specific antifungal techniques may result in more powerful and efficient treatments for invasive fungal infections, according to recent analysis of gene–drug interaction datasets.

Finding novel treatment targets will be facilitated by developments in genomic methods and a growing understanding of fungal survival and virulence processes. Expanding the already small antifungal pipeline will need efforts to create new azole, echinocandin, and polyene derivatives, repurpose existing medications for antifungal usage, and screen for novel natural compounds.

REFERENCE

1. K.M. Pianalto, J.A. Alspaugh, New horizons in antifungal therapy, J. Fungi 2(2016) 1–24.
2. G.D. Brown, D.W. Denning, N.A.R. Gow, S.M. Levitz, M.G. Netea, T.C. White, Hidden killers: human fungal infections, in: Sci. Transl. Med. 4 (2012) 165rv13
3. D. Diekema, S. Arbefeville, L. Boyken, J. Kroeger, M. Pfaller, The changing epidemiology of healthcare-associated candidemia over three decades, Diagn. Microbiol. Infect. Dis. 73 (2012) 45–48.
4. K.A. Marr, H.T. Schlamm, R. Herbrecht, S.T. Rottinghauscott, E.J. Bow, O.A. Cornely, et al., Combination antifungal therapy for invasive aspergillosis, Ann. Intern. Med. 162 (2015) 81–89.
5. D.W. Denning, W.W. Hope, Therapy for fungal diseases: opportunities and priorities, Trends Microbiol. 18 (2010) 195–204.
6. M.V. Castelli, E. Butassi, M.C. Monteiro, L.A. Svetaz, F. Vicente, A. Susana, S.A. Zacchino, Novel antifungal agents: a patent review (2011-present), Expert Opin. Ther. Pat. 24 (2014) 1–16.
7. P. Vandeputte, S. Ferrari, A.T. Coste, Antifungal resistance and new strategies to control fungal infections, Int. J. Microbiol. (2012) 26, http://dx.doi.org/ 10.1155/2012/713687. ID 713687.
8. T. Roemer, D.J. Krysan, Antifungal drug development: challenges, unmet clinical needs, and new approaches, Cold Spring Harb. Perspect. Med. 4 (2014) a019703.
9. D.W. Denning, M.J. Bromley, How to bolster the antifungal pipeline, Science 347 (2015) 1414–1416.
10. J.R. Perfect, Is there an emerging need for new antifungals? Expert Opin. Emerg. Drugs 21 (2016) 129–131, http://dx.doi.org/10.1517/ 14728214.2016.1155554.
11. D.J. Sheehan, C.A. Hitchcock, C.M. Sibley, Current and emerging azole antifungal agents, Clin. Microbiol. Rev. 12 (1999) 40–79.

12. M.A. Ghannoum, Future of antimycotic therapy, Dermatol. Therapy 3 (1997) 104–111.
13. A.J. Carrillo-Munoz, S. Giusiano, P.A. Ezkurra, G. Quindos, Antifungal agents: mode of action in yeast cells, Rev. Esp. Quimioter. 19 (2006) 130–139.
14. J.H. Dawson, M. Sono, Cytochrome P-450 and chloroperoxidase: thiolateligated heme enzymes. Spectroscopic determination of their active-site structures and mechanistic implications of thiolate ligation, Chem. Rev. 87 (1987) 1255–1276.
15. H.V. Bossche, L. Koymans, H. Moereels, P450 inhibitors of use in medical treatment: focus on mechanisms of action, Pharmacol. Ther. 67 (1995) 79– 100.
16. P.K. Shukla, P. Singh, R.K. Yadav, S. Pandey, S.S. Bhunia, Past, present and future of antifungal drug development, Top. Med. Chem. (2016), http://dx.doi. org/10.1007/7355_2016_4.
17. M.T. Nozawa, Effects of antifungal agents on ergosterol biosynthesis in Candida albicans and Trichophyton mentagrophytes: differential inhibitory sites of naphthiomate and miconazole, J. Invest. Dermatol. 85 (1985) 434– 437.
18. A. Pardasani, Oral antifungal agents used in dermatology, Curr. Probl. Dermatol. 11 (2000) 270.
19. P.G. Pappas, J.H. Rex, J.D. Sobel, S.G. Filler, W.E. Dismukes, T.J. Walsh, J.E. Edwards, Guidelines for treatment of candidiasis, Clin. Infect. Dis. 38 (2004) 161–189.
20. T.A. Vincent, Current and future antifungal therapy: new targets for antifungal therapy, Int. J. Antimicrob. Agents 16 (2000) 317.
21. R. Zaragoza, J. Pemán, The diagnostic and therapeutic approach to fungal infections in critical care settings, Adv. Sepsis 6 (2008) 90.
22. G. Petrikkos, A. Skiada, Recent advances in antifungal chemotherapy, Int. J. Antimicrob. Agents 30 (2007) 108–117.
23. R.T. George, C. Jose, F.P. Thomas, Overview of anti-fungal agents, Clin. Chest Med. 30 (2009) 203.
24. V. Nagappan, S. Deresinski, Posaconazole: a broad-spectrum triazole antifungal agent, Clin. Infect. Dis. 45 (2007) 1610–1617.
25. L.R. Peyton, S. Gallagher, M. Hashemzadeh, Triazole antifungals: a review, Drugs Today 51 (2015) 705–718.
26. M.S. Abdel-Kader, M.M. Muharram, New microbial Source of the antifungal allylamine ‘‘Terbinafine”, Saudi Pharm. J. (2016), http://dx.doi.org/10.1016/j. jsps.2016.06.006.
27. A.K. Gupta, J.E. Ryder, E.A. Cooper, Naftifine: a review, J. Cutan. Med. Surg. 12 (2008) 51–58.
28. M. Ghannoum, N. Isham, A. Verma, S. Plaum, A. Fleischer Jr., B. Hardas, In vitro antifungal activity of naftifine hydrochloride against dermatophytes, Antimicrob. Agents Chemother. 57 (2013) 4369–4372.
29. D.G. Sant, S.G. Tupe, C.V. Ramana, M.V. Deshpande, Fungal cell membranepromising drug target for antifungal therapy, J. Appl. Microbiol. (2016),n http://dx.doi.org/10.1111/jam.13301. ISSN 1364-5072.
30. D.L. Mayers, Antimicrobial Drug Resistance: Mechanism of drug Resistance, vol. 1, Humana Press/Springer, Totowa/New York, 2009, p. 299.
31. M.A. Hossain, M.A. Ghannoum, New investigational antifungal agents for treating invasive fungal infections, Expert Opin. Investig. Drugs 9 (2000) 1797–1813.
32. M.A. Hossain, M.A. Ghannoum, New developments in chemotherapy for noninvasive fungal infections, Expert Opin. Investig. Drugs 10 (2001) 1501–1511.
33. D. Andes, In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis, Antimicrob. Agents Chemother. 47 (2003) 1179–1186.
34. T.M. Anderson, M.C. Clay, A.G. Cioffi, K.A. Diaz, G.S. Hisao, M.D. Tuttle, et al., Amphotericin forms an extramembranous and fungicidal sterol sponge, Nat. Chem. Biol. 10 (2014) 400–406, http://dx.doi.org/10.1038/nchembio.1496.
35. Z. Sklenár, V. Scigel, K. Horáckova, O. Slanar, Compounded preparations with nystatin for oral and oromucosal administration, Acta Pol. Pharm. Drug Res. 70 (2013) 759–762.
36. P. Lalitha, V.R. Kumar, N.V. Prajna, A.W. Fothergill, In vitro natamycin susceptibility of ocular isolates of Fusarium and Aspergillus species: comparison of commercially formulated natamycin eye drops to pharmaceutical-grade powder, J. Clin. Microbiol. 46 (10) (2008) 3477–3478.
37. M.A. Farid, H.A. El-Enshasy, A.I. El-Diwany, E.S.A. El-Sayed, Optimization of the cultivation medium for natamycin production by Streptomyces natalensis, J. Basic Microbiol. 40 (2000) 157–166.
38. S.B. Zotchev, Polyene macrolide antibiotics and their applications in human therapy, Curr. Med. Chem. 10 (2003) 211–223.
39. R. Laniado-Laborín, M.N. Cabrales-Vargas, Amphotericin B: side effects and toxicity, Rev. Iberoam. Micol. 26 (2009) 223–227.
40. P. Caffrey, S. Lynch, E. Flood, S. Finnan, M. Oliynyk, Amphotericin biosynthesis in Streptomyces nodosus: deductions from analysis of polyketide synthase and late genes, Chem. Biol. 8 (2001) 713–723.
41. A. Lemke, A.F. Kiderlen, O. Kayser, Amphotericin B, Appl. Microbiol. Biotechnol. 68 (2005) 151–162.
42. F.C. Odds, A.J.P. Brown, N.A.R. Gow, Antifungal agents: mechanisms of action, Trends Microbiol. 11 (2003) 272–279.
43. W.J. Gibbs, R.H. Drew, J.R. Perfect, Liposomal amphotericin B: clinical experience and perspectives, Expert Rev. Anti-Infect. Ther. 3 (2005) 167–181.
44. R.D. Santo, Natural products as antifungal agents against clinically relevant pathogens, Nat. Prod. Rep. 27 (2010) 1084–1098.
45. H. Kakeya, Y. Miyazaki, H. Senda, T. Kobayashi, M. Seki, K. Izumikawa, et al., Efficacy of SPK-843, a novel polyene antifungal, in comparison with

amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis, Antimicrob. Agents Chemother. 52 (2008) 1868–1870.
46. B. Dupont, Overview of the lipid formulations of amphotericin B, J. Antimicrob. Chemother. 49 (2002) 31–36.
47. P. Chandrasekar, Management of invasive fungal infections: a role for polyenes, J. Antimicrob. Chemother. 66 (2011) 457–465.
48. L. Zarif, J.R. Graybill, D. Perlin, R.J. Mannino, Cochleates: new lipid-based drug delivery system, J. Liposome Res. 10 (2000) 523–538.
49. R. Falk, A.J. Domb, I. Polacheck, A novel injectable water-soluble amphotericin B-arabinogalactan conjugate, Antimicrob. Agents Chemother. 43 (1999) 1975–1981.
50. T. Lorand, B. Kocsis, Recent advances in antifungal agents, Mini Rev. Med. Chem. 7 (2007) 900–911.
51. A.J. Sucher, E.B. Chahine, H.E. Balcer, Echinocandins: the newest class of antifungals, Ann. Pharmacother. 43 (2009) 1647–1657.
52. P.K. Mukherjee, D. Sheehan, L. Puzniak, H. Schlamm, M.A. Ghannoum, Echinocandins: are they all the same? J. Chemother. 23 (2011) 319–325, http://dx.doi.org/10.1179/joc.2011.23.6.319.
53. J.A. Vazquez, J.D. Sobel, Anidulafungin: a novel echinocandin, Clin. Infect. Dis. 43 (2006) 215–222.
54. G. Eschenauer, D.D. DePestel, P.L. Carver, Comparison of echinocandin antifungals, Ther. Clin. Risk Manag. 3 (2007) 71–97.
55. J.M. Valgus, What's new in antifungals? Curr. Infect. Dis. Rep. 5 (2003) 16–21.
56. D. Andes, K. Marchillo, J. Lowther, A. Bryskier, T. Stamstad, R. Conklin, In vivo pharmacodynamics of HMR 3270, a Glucan synthase inhibitor, in a murine candidiasis model, Antimicrob. Agents Chemother. 47 (2003) 1187–1192.
57. M.A. Pfaller, S.A. Messer, P.R. Rhomberg, R.N. Jones, M. Castanheira, Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates, J. Antimicrob. Chemother. (2016), http://dx.doi.org/10.1093/jac/dkw214.
58. P. Gershkovich, E. Wasan, M. Lin, O. Sivak, C.G. Leon, J.G. Clement, K.M. Wasan, Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation, J. Antimicrob. Chemother. 64 (2009) 101–108, http://dx.doi.org/10.1093/jac/ dkp140.
59. R.A. Akins, An update on antifungal targets and mechanisms of resistance in Candida albicans, Med. Mycol. 43 (2005) 285–318.
60. M.P. Arevalo, A.J. Carillo-Munoz, J. Salgado, D. Cardenes, S. Brió, G. Quindós, A. Espinel-Ingroff, Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method, J. Antimicrob. Chemother. 51 (2003) 163–166.
61. M.F. Vicente, A. Basilio, A. Cabello, F. Peláez, Microbial natural products as a source of antifungals, Clin. Microbiol. Infect. 9 (2003) 15–32.
62. R. Rollin-Pinheiro, A. Singh, E. Barreto-Bergter, M. Del Poeta, Sphingolipids as targets for treatment of fungal infections, Future Med. Chem. 8 (2016) 1469– 1484.
63. K. Takesako, K. Ikai, F. Haruna, M. Endo, K. Shimanaka, E. Sono, et al., Aureobasidins, new antifungal antibiotics taxonomy, fermentation, isolation and properties, J. Antibiot. 44 (1991) 919–924.
64. W. Zhong, M. Jeffries, N.H. Georgopapadakou, Inhibition of inositol phosphorylceramide synthase by aureobasidin A in Candida and Aspergillus species, Antimicrob. Agents Chemother. 44 (2000) 651–653.
65. T. Hashida-Okado, A. Ogawa, M. Endo, R. Yasumoto, K. Takesako, I. Kato, AUR1, a novel gene conferring aureobasidin resistance on Saccharomyces cerevisiae: a study of defective morphologies in Aur1p-depleted cells, Mol. Gen. Genet. (Tokyo) 251 (1996) 236–244.